Form 8-K - Current report

false 0001503802 0001503802 2024-11-20 2024-11-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 20, 2024

 

 

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware		001-36167		26-3931704
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

85 Wells Avenue, 2nd Floor
Newton, Massachusetts		02459
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: [phone]

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		KPTI		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 20, 2024, Karyopharm Therapeutics Inc. (the “Company”) announced the appointment of Kristin Abate, the Company’s Vice President, Accounting, Corporate Controller and Assistant Treasurer, as the Company’s Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company’s interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company’s principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as the Company’s interim principal financial officer.

Ms. Abate, age 39, has over 15 years of experience in finance and has been employed by the Company since July 2019 in a variety of roles with increasing seniority. She served as Director, Accounting & Reporting from July 2019 to July 2020, Senior Director, Accounting & Reporting from July 2020 to May 2022, Executive Director of Accounting & Corporate Controller from May 2022 to August 2023, Vice President, Accounting & Corporate Controller from August 2023 to September 2024 and most recently, as Vice President, Accounting, Corporate Controller and Assistant Treasurer since September 2024. Prior to joining the Company, Ms. Abate worked in various roles as a public accountant from 2007 to July 2019 at PricewaterhouseCoopers LLP. Ms. Abate received a B.S. in Business Administration from Bryant University and a Masters of Science in Accountancy from Boston College and is a certified public accountant.

There are no family relationships between Ms. Abate and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. There are no transactions in which Ms. Abate has an interest requiring disclosure under Item 404(a) of Regulation S-K.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				KARYOPHARM THERAPEUTICS INC.
Date: November 20, 2024				By:		/s/ Michael Mano
						Michael Mano
						Senior Vice President, General Counsel and Secretary

Document and Entity Information	Nov. 20, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001503802
Document Type	8-K
Document Period End Date	Nov. 20, 2024
Entity Registrant Name	Karyopharm Therapeutics Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-36167
Entity Tax Identification Number	26-3931704
Entity Address, Address Line One	85 Wells Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	Newton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02459
City Area Code	(617)
Local Phone Number	658-0600
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.0001 par value
Trading Symbol	KPTI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---